Boehringer Ingelheim to Use Seqster Platform

Published on: 

Patients in all studies can consent to longitudinal data use to accelerate RWE

Patient-centric healthcare data technology provider Seqster PDM, Inc. announced a three-year partnership with Boehringer Ingelheim to use the SeqsterOS to close the Real World Evidence (RWE) gap. To that end, SeqsterOS will provide patients in all of BI's studies access and engagement with longitudinal RWD, with full patient consent and control.

Read more about the partnership.


Listen to a podcast with Seqster CEO & Co-founder Ardy Arianpour.